178,377 Shares in Repligen Corporation $RGEN Acquired by Blue Whale Capital LLP

Blue Whale Capital LLP acquired a new stake in Repligen Corporation (NASDAQ:RGEN) during the 2nd quarter, Holdings Channel.com reports. The fund acquired 178,377 shares of the biotechnology company’s stock, valued at approximately $24,338,000. Repligen comprises approximately 0.8% of Blue Whale Capital LLP’s holdings, making the stock its 23rd largest position.

A number of other institutional investors and hedge funds have also modified their holdings of RGEN. Measured Wealth Private Client Group LLC purchased a new position in shares of Repligen in the third quarter worth $29,000. Rachor Investment Advisory Services LLC purchased a new stake in shares of Repligen during the 4th quarter valued at about $33,000. Los Angeles Capital Management LLC bought a new position in Repligen in the fourth quarter worth approximately $36,000. Northwestern Mutual Wealth Management Co. bought a new position in Repligen in the 2nd quarter worth $52,000. Finally, Farther Finance Advisors LLC grew its holdings in Repligen by 61.8% during the fourth quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 128 shares during the period. Institutional investors own 97.64% of the company’s stock.

Analysts Set New Price Targets

RGEN has been the topic of several recent research reports. Evercore reaffirmed an “outperform” rating and issued a $160.00 price objective on shares of Repligen in a research note on Monday, July 6th. JPMorgan Chase & Co. boosted their price objective on Repligen from $165.00 to $175.00 and gave the company an “overweight” rating in a research note on Wednesday, July 29th. Royal Bank Of Canada assumed coverage on shares of Repligen in a report on Thursday, May 14th. They issued an “outperform” rating and a $160.00 target price for the company. HSBC decreased their target price on shares of Repligen from $170.00 to $150.00 and set a “buy” rating on the stock in a research note on Wednesday, June 3rd. Finally, Wells Fargo & Company lifted their price target on shares of Repligen from $180.00 to $185.00 and gave the company an “overweight” rating in a report on Thursday, July 30th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, Repligen has a consensus rating of “Buy” and a consensus target price of $166.43.

Repligen Stock Performance

Shares of RGEN stock opened at $181.13 on Monday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.64 and a current ratio of 9.05. The stock has a fifty day simple moving average of $147.16 and a two-hundred day simple moving average of $131.75. The firm has a market capitalization of $10.22 billion, a PE ratio of 248.12, a PEG ratio of 3.31 and a beta of 1.03. Repligen Corporation has a 52-week low of $100.99 and a 52-week high of $188.73.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 EPS for the quarter, beating the consensus estimate of $0.45 by $0.09. The business had revenue of $204.13 million for the quarter, compared to the consensus estimate of $201.59 million. Repligen had a return on equity of 5.30% and a net margin of 5.29%.The business’s revenue was up 11.9% on a year-over-year basis. During the same period in the previous year, the business earned $0.26 earnings per share. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. On average, analysts predict that Repligen Corporation will post 2.06 EPS for the current fiscal year.

Insider Transactions at Repligen

In related news, CFO Jason K. Garland sold 733 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total value of $106,285.00. Following the transaction, the chief financial officer directly owned 19,359 shares of the company’s stock, valued at approximately $2,807,055. The trade was a 3.65% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.60% of the company’s stock.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.